Literature DB >> 26820666

Prevalence of Dystonia in Antioquia, Colombia.

Juan Marcos Solano Atehortúa1, Sandra Patricia Isaza Jaramillo, Ana Rendón Bañol, Omar Buritica Henao.   

Abstract

BACKGROUND: There are few published epidemiological studies concerning dystonia. Its true prevalence has been difficult to establish. There is no data published in Latin America on this matter.
METHODS: In this study the prevalence of dystonias in the Department of Antioquia (Colombia) was estimated using a capture-recapture methodology with log-linear modeling, including cases in 3 centers for neurological referrals that cover the Department of Antioquia from 2007 to 2012.
RESULTS: The overall prevalence was 712 per 1,000,000 (95% CI 487-937). Of the total of 874 patients, 79% had primary dystonias, and 75.5% had focal dystonias. The delay in diagnosis was longer for primary dystonias, with a median of 1 year.
CONCLUSION: We found a high prevalence of dystonias in Antioquia. The frequency of the different types of dystonias, as well as the demographic characteristics of our patients, is similar to data from other populations of the world.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 26820666     DOI: 10.1159/000443834

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  3 in total

1.  Adult-onset idiopathic dystonia: A national data-linkage study to determine epidemiological, social deprivation, and mortality characteristics.

Authors:  Grace A Bailey; Anna Rawlings; Fatemeh Torabi; Owen Pickrell; Kathryn J Peall
Journal:  Eur J Neurol       Date:  2021-10-15       Impact factor: 6.288

Review 2.  The Prevalence of Idiopathic or Inherited Isolated Dystonia: A Systematic Review and Meta-Analysis.

Authors:  Alex Medina; Christelle Nilles; Davide Martino; Catherine Pelletier; Tamara Pringsheim
Journal:  Mov Disord Clin Pract       Date:  2022-08-24

3.  The prevalence of adult-onset isolated dystonia in Finland 2007-2016.

Authors:  Rebekka Ortiz; Filip Scheperjans; Tuomas Mertsalmi; Eero Pekkonen
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.